CSIMarket
 
Scynexis Inc   (NASDAQ: SCYX)
Other Ticker:  
 
 
Price: $1.1800 $0.09 8.257%
Day's High: $1.2176 Week Perf: 7.27 %
Day's Low: $ 1.09 30 Day Perf: -16.31 %
Volume (M): 288 52 Wk High: $ 3.07
Volume (M$): $ 340 52 Wk Avg: $1.61
Open: $1.09 52 Wk Low: $0.10



 Market Capitalization (Millions $) 57
 Shares Outstanding (Millions) 49
 Employees 99
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Scynexis Inc
Scynexis Inc is a biotechnology company that focuses on developing and commercializing highly innovative therapies to address serious and life-threatening fungal infections. Founded in 2000 and headquartered in Jersey City, New Jersey, USA, Scynexis has an experienced leadership team that is dedicated to advancing medical science and improving the lives of patients worldwide.

Scynexis develops therapies for a wide range of fungal infections, including Candida and Aspergillosis, which are often associated with high morbidity and mortality rates. Their lead product candidate, ibrexafungerp (formerly SCY-078), is a novel antifungal drug that acts by inhibiting the fungal enzyme glucan synthase, which is required for the production of fungal cell walls. Ibrexafungerp has demonstrated that it can provide broad-spectrum activity against a range of fungal species and is expected to have a lower risk of developing drug resistance when compared to other available antifungal agents.

In addition to its lead product candidate, Scynexis has an extensive pipeline of antifungal products in development. They are exploring the potential of using ibrexafungerp to target other types of fungal infections, including those caused by drug-resistant strains. Also, Scynexis has developed a proprietary platform technology for the discovery and development of novel antifungal compounds, which they believe can significantly advance the treatment of severe fungal infections.

Scynexis has been successful in raising significant amounts of capital, enabling it to fund its operations and research activities. Moreover, they have established partnerships with reputable organizations, such as the National Institutes of Health (NIH), to advance their research and develop breakthrough treatments. Their partnerships also extend to commercialization deals with established pharmaceutical companies, such as Jiangsu Hengrui Medicine Co., Ltd. and IMMY Inc.

Overall, Scynexis is a pioneering biotechnology company that is dedicated to advancing the field of antifungal therapy. They aim to provide innovative, effective treatments to patients suffering from serious fungal infections and improve overall patient outcomes. Their commitment to scientific excellence and partnership collaborations make them a leader in the field of antifungal research and development.


   Company Address: 1 Evertrust Plaza Jersey City 7302 NJ
   Company Phone Number: 884-5485   Stock Exchange / Ticker: NASDAQ SCYX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMPH   -9.84%    
CDTX        11.71% 
• View Complete Report
   



Clinical Study

SCYNEXIS Advances Antifungal Innovation Pioneering the Fight Against Invasive Fungal Infections with SCY-247

Published Sat, Dec 28 2024 3:59 PM UTC

In a significant stride towards combating the challenge posed by invasive fungal infections, SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated dosing in its Phase 1 clinical trial of SCY-247, a second-generation triterpenoid antifungal agent. Announced on December 18, 2024, this milestone is not only a testament to SCYNEXIS s commitment to developing innovative treatments but als...

Clinical Study

SCYNEXIS to Showcase Promising Preclinical Advances of SCY-247 at IDWeek 2024 A New Frontier in Antifungal Therapy

Published Thu, Oct 3 2024 12:00 PM UTC

In a significant stride towards addressing the ever-growing challenge of difficult-to-treat and drug-resistant infections, SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that it will present groundbreaking preclinical data on its second-generation fungicidal compound, SCY-247, at IDWeek 2024. Scheduled to take place from October 16-19, 2024, in Los Angeles, CA, this event will ...

Financing Agreement

SCYNEXIS Secures $10 Million Milestone Payment from GSK Upon Delivery of Completed FURI, CARES, and NATURE Clinical Study Reports

Published Tue, Jul 23 2024 11:00 AM UTC

Interpreting the Facts: Despite a Net Increase in Borrowings, Scynexis Inc Enhances Tangible Leverage Ratio
In the third quarter of 2023, Scynexis Inc saw a net increase in borrowings of -8.45%, yet managed to enhance its Tangible Leverage Ratio to 0.62. This surpasses the company s typical average Tangible Leverage Ratio. Looking back at the trailing twelve months, the ...

Product Service News

Preclinical Efficacy of SCY-247, a Second Generation Fungerp Candidate, Presented at ESCMID Global Congress 2024

Published Tue, Apr 30 2024 8:05 PM UTC

SCYNEXIS, Inc., a leading biotechnology company focused on developing breakthrough treatments for challenging and drug-resistant infections, recently unveiled groundbreaking preclinical efficacy data for its second generation fungerp candidate, SCY-247. The data was presented at the ESCMID Global 2024 congress (formerly known as ECCMID) in Barcelona, Spain.SCYNEXIS, Inc. has...

Product Service News

SCYNEXIS Unveils Groundbreaking Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Published Mon, Jan 29 2024 10:15 PM UTC

SCYNEXIS Presents Promising Preclinical Data on Second Generation Fungerp SCY-247 against MucormycosisJERSEY CITY, N.J., Jan. 29, 2024 - SCYNEXIS, Inc. (NASDAQ: SCYX), a pioneering biotechnology company specializing in innovative medicines to combat challenging-to-treat and drug-resistant infections, unveiled compelling preclinical efficacy data today at the 11th Advances A...







Scynexis Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com